Anti-PD-1/PD-L1 antibodies have shown clinical advantages in more than 15 cancer types, but most patients with advanced HCC have not yet obtained clinical benefit from these drugs, which indicates that the immunosuppressive mechanism in the tumor microenvironment may of a great essence [56]. This evidence concerns the gene CD274 and cancer.